Advertisement

Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma

  • Dai OgataEmail author
  • Tetsuya Tsuchida
Skin Cancer (T Ito, Section Editor)
  • 105 Downloads
Part of the following topical collections:
  1. Topical Collection on Skin Cancer

Opinion statement

Advanced (i.e., unresectable) cutaneous squamous cell carcinoma (cSCC) is a rare condition with a dismal prognosis. Although less than 5% of cSCC patients develop metastases or local recurrence after complete excision, advanced cSCC is difficult to treat. These conditions tend to develop in elderly patients, although, at times, metastases are noted in middle-aged patients. Once metastasis occurs in cSCC, the 10-year survival rates fall to less than 20% for patients with regional lymph node involvement and less than 10% for patients with distant metastases, indicating that cSCC can be difficult to treat effectively when it is advanced. Traditionally, platinum-based therapy has been considered as a conventional option for advanced cSCC. It is efficacious to some degree, but the toxic effects of the combination treatments often prohibit their use in elderly patients. It has been a decade since the development of epidermal growth factor receptor (EGFR) inhibitors as agents that are less toxic. However, evidence regarding systemic therapy for advanced cSCC is limited because of a lack of high-quality prospective studies. Remarkably, the US Food and Drug Administration (FDA) approved an anti-PD-1 antibody treatment (cemiplimab) for the treatment of patients who are not candidates for curative surgery or curative radiation. It will be a promising treatment option for these types of rare conditions.

Keywords

Squamous cell carcinoma of the skin Chemotherapy Targeted therapy Immunotherapy Radiotherapy Metastasis Unresectable 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dai Ogata and Tetsuya Tsuchida declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. 2009;35:574–85.CrossRefGoogle Scholar
  2. 2.
    Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51:1989–2007.CrossRefGoogle Scholar
  3. 3.
    Hirshoren N, Danne J, Dixon BJ, Magarey M, Kleid S, Webb A, et al. Prognostic markers in metastatic cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2017;39(4):772–8.CrossRefGoogle Scholar
  4. 4.
    Wang JT, Palme CE, Wang AY, Morgan GJ, Gebski V, Veness MJ. In patients with metastatic cutaneous head and neck squamous cell carcinoma to cervical lymph nodes, the extent of neck dissection does not influence outcome. J Laryngol Otol. 2013;127(Suppl 1):S2–7.CrossRefGoogle Scholar
  5. 5.
    Forest VI, Clark JJ, Veness MJ, Milross C. N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers. Cancer. 2010;116(5):1298–304.CrossRefGoogle Scholar
  6. 6.
    Schmidt C, Martin JM, Khoo E, Plank A, Grigg R. Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center. Head Neck. 2015;37(12):1808–15.CrossRefGoogle Scholar
  7. 7.
    Bejar C, Maubec E. Therapy of advanced squamous cell carcinoma of the skin. Curr Treat Options in Oncol. 2014;15(2):302–20.CrossRefGoogle Scholar
  8. 8.
    Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419–26.CrossRefGoogle Scholar
  9. 9.
    Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012;18(5):1435–46.CrossRefGoogle Scholar
  10. 10.
    Weinberg AS, Ogle CA, Shim EK. Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg. 2007;33:885–99.PubMedGoogle Scholar
  11. 11.
    •• Migden MR, Rischin D, Schmults CD, Hauschild A, Lewis KD, Chung CH, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–51 This article is the first cemiplimab, an anti-PD-L1 antibody, prospective trial in patients with advanced cSCC for evaluating efficacy and safety. It indicates anti-PD-L1 antibody therapy significantly improves the prognosis of advanced cSCC patients.CrossRefGoogle Scholar
  12. 12.
    Ribero S, Stucci LS, Daniels GA, Borradori L. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence? Curr Opin Oncol. 2017;29(2):129–35.PubMedGoogle Scholar
  13. 13.
    Boukamp P. Nonmelanoma skin cancer: what drives tumor development and progression? Carcinogenesis. 2005;26:1657–67.CrossRefGoogle Scholar
  14. 14.
    Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer. 1993;72:2186–9.CrossRefGoogle Scholar
  15. 15.
    Kim Y, He YY. Ultraviolet radiation-induced nonmelanoma skin cancer: regulation of DNA damage repair and inflammation. Genes Dis. 2014;1:188–98.CrossRefGoogle Scholar
  16. 16.
    Mukhtar H, Elmets CA. Photocarcinogenesis: mechanisms, models and human health implications. Photochem Photobiol. 1996;63(4):356–7.CrossRefGoogle Scholar
  17. 17.
    Freeman A, Bridge JA, Maruthayanar P, Overgaard NH, Jung JW, Simpson F, et al. Comparative immune phenotypic analysis of cutaneous squamous cell carcinoma and intraepidermal carcinoma in immune-competent individuals: proportional representation of CD8þ T-cells but not FoxP3þ regulatory T-cells is associated with disease stage. PLoS One. 2014;9:e110928.CrossRefGoogle Scholar
  18. 18.
    Roper E, Lum T, Palme CE, Ashford B, Ch’ng S, Ranson M, et al. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology. 2017;49(5):499–505.CrossRefGoogle Scholar
  19. 19.
    Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–56.CrossRefGoogle Scholar
  20. 20.
    • Markham A, Duggan S. Cemiplimab: first global approval. Drugs. 2018;78(17):1841–6 This article summarizes the milestones in the development of cemiplimab and ongoing clinical trials.CrossRefGoogle Scholar
  21. 21.
    FDA. FDA approves first treatment for advanced form of the second most common skin cancer. 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622044.htm. Accessed 2 Jan 2019.
  22. 22.
    Chang AL, Kim J, Luciano R, Sullivan-Chang L, Colevas AD. A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor. JAMA Dermatol. 2016;152:106–8.CrossRefGoogle Scholar
  23. 23.
    Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374(9):896–8.CrossRefGoogle Scholar
  24. 24.
    Borradori L, Sutton B, Shayesteh P, Daniels GA. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol. 2016;175(6):1382–6.CrossRefGoogle Scholar
  25. 25.
    Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Fröhling S, Penzel R, et al. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2017;176(2):498–502.CrossRefGoogle Scholar
  26. 26.
    Hauschild A, Eichstaedt J, Möbus L, Kähler K, Weichenthal M, Schwarz T, et al. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. Eur J Cancer. 2017;77:84–7.CrossRefGoogle Scholar
  27. 27.
    Deinlein T, Lax SF, Schwarz T, Giuffrida R, Schmid-Zalaudek K, Zalaudek I. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature. Eur J Cancer. 2017;83:99–102.CrossRefGoogle Scholar
  28. 28.
    Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, Krueger JG, et al. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol. 2017;153(4):299–303.CrossRefGoogle Scholar
  29. 29.
    Tran DC, Colevas AD, Chang AL. Follow-up on programmed cell death 1 inhibitor for cutaneous squamous cell carcinoma. JAMA Dermatol. 2017;153(1):92–4.CrossRefGoogle Scholar
  30. 30.
    Degache E, Chrochet J, Simon N, Tardieu M, Trabelsi S, Moncourier M, et al. Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2018;32(7):e257–e258s.  https://doi.org/10.1111/jdv.14371.CrossRefPubMedGoogle Scholar
  31. 31.
    Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016;4:70.CrossRefGoogle Scholar
  32. 32.
    Day F, Kumar M, Fenton L, Gedye C. Durable response of metastatic squamous cell carcinoma of the skin to ipilimumab immunotherapy. J Immunother. 2017;40(1):36–8.CrossRefGoogle Scholar
  33. 33.
    Merck & Co., Inc. Prescribing information: KEYTRUDA (pembrolizumab) injection, for intravenous use. 2017. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed 2 Jan 2019.
  34. 34.
    Bristol-Myers Squibb Company. Prescribing information: OPDIVO (nivolumab) injection, for intravenous use. 2017. https://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed 2 Jan 2019.
  35. 35.
    •• Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67 This article describes randomized, open-label, phase 3 trial with recurrent squamous-cell carcinoma of the head and neck and nivolumab prolonged survival, as compared with standard therapy.CrossRefGoogle Scholar
  36. 36.
    • LQM C, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016;34(32):3838–45 This article describes a phase Ib, multicenter, nonrandomized, multicohort study of pembrolizumab in patients with advanced solid tumors.CrossRefGoogle Scholar
  37. 37.
    • Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65 This article describes an open-label, multicenter, phase 1b trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.CrossRefGoogle Scholar
  38. 38.
    Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95–106.CrossRefGoogle Scholar
  39. 39.
    O’Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110:2614–27.CrossRefGoogle Scholar
  40. 40.
    Fong L, Small EJ. Anticytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275–83.CrossRefGoogle Scholar
  41. 41.
    Manson G, Norwood J, Marabelle A, Kohrt H, Houot R. Biomarkers associated with checkpoint inhibitors. Ann Oncol. 2016;27:1199–206.CrossRefGoogle Scholar
  42. 42.
    Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma. ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT02760498
  43. 43.
    Study of pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin. ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT02883556
  44. 44.
    Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74.CrossRefGoogle Scholar
  45. 45.
    Cemiplimab in treating participants with recurrent stage III-IV hand neck squamous cell cancer before surgery. ClinicalTrials.gov. 1999. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT03565783
  46. 46.
    Pembrolizumab in treating patients with rare tumors that cannot be removed by surgery or are metastatic. ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT02721732
  47. 47.
    T-VEC in non-melanoma skin cancer (20139157 T-VEC). ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT03458117
  48. 48.
    Phase 1 study of CK-301 as a single agent in subjects with advanced cancers. ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT03212404
  49. 49.
    The UNSCARRed study: UNresctable Squamous Cell Carcinoma treated with Avelumab and Radical Radiotherapy (UNSCARRed). ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT03737721
  50. 50.
    Pembrolizumab combined with cetuximab for treatment of recurrent/metastatic head & neck squamous cell carcinoma. ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT03082534
  51. 51.
    Talimogene laherparepvec and nivolumab in treating patients with refractory lymphomas or advanced or refractory non-melanoma skin cancers. ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT02978625
  52. 52.
    A Phase 1b dose escalation/expansion study of abexinostat in combination with pembrolizumab in patients with advanced solid tumor malignancies. ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT03590054
  53. 53.
    Trial of MG1-MAGEA3 with Ad-MAGEA3 and pembrolizumab in patients with previously treated metastatic melanoma or cutaneous squamous cell carcinoma (Pelican). ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT03773744
  54. 54.
    Cobimetinib and atezolizumab in advanced rare tumors. ClinicalTrials.gov. 2019. Accessed 2 Jan 2019. https://clinicaltrials.gov/ct2/show/NCT03108131
  55. 55.
    William WN Jr, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single-arm phase II clinical trial. J Am Acad Dermatol. 2017;77:1110–3.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of DermatologySaitama Medical UniversitySaitamaJapan

Personalised recommendations